In a recent paper published by the journal Scientific Reports, Dr. Pedro Brugarolas and his colleagues describe the development and testing in animal models of a new PET tracer for demyelination. Their new tracer is based on the MS drug 4-aminopyridine (4AP, dalfampridine) which binds to potassium channels in demyelinated axons allowing the visualization of demyelinated lesions in animal models of MS noninvasively.
Dr. Heidi Jacobs along with Dr. Keith Johnson have published a paper in Nature Neuroscience entitled “Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals”.
Cerveau Technologies Inc. signed an agreement with the MGH Gordon Center to support multiple projects over the next several years. These research projects are for studies of an early stage imaging agent (MK-6240) to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.
Dr. Keith Johnson has been named to the 2017 “Highly Cited Researchers” list from Clarivate Analytics.
The list recognized 3,538 highly cited researchers in 21 fields of the sciences and social sciences. These researchers have distinguished themselves by publishing a high number of papers that rank in the top one percent most-cited in their respective fields internationally over a recent 11-year period.